<p>Three Bridge Wealth Advisors LLC 在第二季度购买了 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免费报告) 的新股份，根据该公司在最近向证券交易委员会的备案中披露。这家机构投资者购买了 454 股公司股票，价值约为 243,000 美元。</p>
<p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
<ul>
<li>看涨还是看跌？评估动物医疗股票</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也对该股票的持仓进行了调整。Red Spruce Capital LLC 在第二季度将其在 IDEXX Laboratories 的持股增加了 1.1%。Red Spruce Capital LLC 现在拥有 1,701 股公司股票，价值 912,000 美元，在此期间又购买了 19 股。Rise Advisors LLC 在第二季度将其在 IDEXX Laboratories 的持仓提高了 3.9%。Rise Advisors LLC 现在拥有 562 股公司股票，价值 301,000 美元，在上个季度又购买了 21 股。Sage Mountain Advisors LLC 在第一季度将其在 IDEXX Laboratories 的持仓提高了 3.8%。Sage Mountain Advisors LLC 现在拥有 635 股公司股票，价值 267,000 美元，在上个季度又购买了 23 股。Great Lakes Advisors LLC 在第一季度将其在 IDEXX Laboratories 的持仓提高了 0.9%。Great Lakes Advisors LLC 现在拥有 2,567 股公司股票，价值 1,078,000 美元，在上个季度又购买了 23 股。最后，PDS Planning Inc 在第一季度将其在 IDEXX Laboratories 的持仓提高了 3.9%。PDS Planning Inc 现在拥有 641 股公司股票，价值 269,000 美元，在上个季度又购买了 24 股。机构投资者和对冲基金持有公司 87.84% 的股票。</p>
<h2>IDEXX Laboratories 股票表现</h2>
<p>NASDAQ IDXX 周五开盘价为 631.19 美元。该公司的 50 日移动平均线为 634.52 美元，200 日移动平均线为 535.57 美元。公司的债务与股本比率为 0.31，速动比率为 0.79，流动比率为 1.11。该股票的市值为 505 亿美元，市盈率为 52.56，市盈增长比率为 4.09，贝塔值为 1.58。IDEXX Laboratories, Inc. 的 52 周低点为 356.14 美元，52 周高点为 688.12 美元。</p>
<p>IDEXX Laboratories (NASDAQ:IDXX - 获取免费报告) 最近于 8 月 4 日星期一发布了季度财报。该公司报告季度每股收益为 3.63 美元，超出分析师一致预期的 3.28 美元，超出幅度为 0.35 美元。IDEXX Laboratories 的净利润率为 24.41%，股本回报率为 64.42%。该季度的营业收入为 11.1 亿美元，而分析师预期为 10.6 亿美元。去年同期，该公司每股收益为 2.44 美元。与去年同期相比，IDEXX Laboratories 本季度的收入增长了 10.6%。IDEXX Laboratories 已设定 2025 财年的每股收益指导为 12.400-12.760 美元。平均而言，卖方分析师预计 IDEXX Laboratories, Inc. 本年度将发布 11.93 美元的每股收益。</p>
<h2>IDEXX Laboratories 的内部买卖</h2>
<p>在相关消息中，执行副总裁 Nimrata Hunt 于 8 月 6 日星期三出售了 7,143 股公司的股票。股票以 630.43 美元的平均价格出售，总交易额为 4,503,161.49 美元。交易后，该执行副总裁直接持有 18,007 股公司股票，价值约为 11,352,153.01 美元。这笔交易代表其持股减少了 28.40%。该交易已在向证券交易委员会的法律备案中披露，相关信息可通过 SEC 网站获取。此外，首席执行官 Jonathan Jay Mazelsky 于 8 月 6 日星期三出售了 29,260 股公司的股票。股票以 631.98 美元的平均价格出售，总交易额为 18,491,734.80 美元。交易后，首席执行官直接持有 83,311 股公司股票，价值约为 52,650,885.78 美元。这代表其持股减少了 25.99%。该销售的披露信息可以在这里找到。内部人士在上个季度出售了 54,057 股公司股票，价值 34,293,468 美元。公司内部人士持有公司 0.98% 的股票。</p>
<h2>分析师评级上调和下调</h2>
<p>几家券商最近对 IDXX 发表了评论。华尔街禅在 9 月 28 日星期日的报告中将 IDEXX Laboratories 的股票评级从 “强力买入” 下调至 “买入”。BTIG Research 在 8 月 5 日星期二的报告中将 IDEXX Laboratories 的目标价格从 545.00 美元上调至 785.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 9 月 27 日星期六的报告中重申了对 IDEXX Laboratories 的 “买入（b-）” 评级。摩根大通在 8 月 4 日星期一的报告中将 IDEXX Laboratories 的目标价格从 550.00 美元上调至 675.00 美元，并给予该股票 “增持” 评级。最后，Jefferies Financial Group 在 7 月 1 日星期二开始覆盖 IDEXX Laboratories 的股票。他们设定了 “买入” 评级和 625.00 美元的目标价格。一位研究分析师对该股票给予了强力买入评级，七位给予了买入评级，四位对该公司给予了持有评级。根据 MarketBeat.com，该公司目前的共识评级为 “适度买入”，共识目标价格为 656.50 美元。</p>
<p><strong>阅读我们最新的 IDXX 股票分析</strong></p>
<h2>IDEXX Laboratories 公司简介</h2>
<p>（免费报告）</p>
<p>IDEXX Laboratories, Inc. 主要开发、制造和分销产品，服务于非洲、亚太地区、加拿大、欧洲、拉丁美洲及国际市场的伴侣动物兽医、牲畜和家禽、乳制品及水质检测市场。该公司通过三个部门运营：伴侣动物组；水质产品；以及牲畜、家禽和乳制品。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 IDEXX 实验室</li>
<li>比较和交易高市盈率股票</li>
<li>为什么没人谈论的贵金属可能是你最好的投资选择</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>便宜的 Chipotle？为什么 CMG 股票可能准备反弹</li>
<li>在 52 周高点盈利交易股票</li>
<li>3 只工业股票准备从美联储降息和支出中受益</li>
</ul>
<p><strong>想看看其他对 IDXX 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取 IDEXX 实验室公司（NASDAQ:IDXX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 IDEXX 实验室吗？</h2>
<p>在你考虑 IDEXX 实验室之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而 IDEXX 实验室并不在名单上。</p>
<p>虽然 IDEXX 实验室目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IDEXX实验室

<p>Three Bridge Wealth Advisors LLC 在第二季度收购了 IDEXX Laboratories, Inc. (NASDAQ:IDXX) 的新股份，购买了 454 股，价值约为 243,000 美元。其他机构投资者也调整了他们在该股票上的持仓。IDEXX Laboratories 报告了强劲的季度收益，收入为 11.1 亿美元，每股收益为 3.63 美元，超出分析师的预期。该股票目前的交易价格为 631.19 美元，市值为 505 亿美元。近期注意到内部人士的抛售，执行官们出售了大量股份</p>

<p>Three Bridge Wealth Advisors LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor purchased 454 shares of the company's stock, valued at approximately $243,000.</p>
<div class="lb-trans"><p>Three Bridge Wealth Advisors LLC 在第二季度购买了 IDEXX Laboratories, Inc. (NASDAQ:IDXX - 免费报告) 的新股份，根据该公司在最近向证券交易委员会的备案中披露。这家机构投资者购买了 454 股公司股票，价值约为 243,000 美元。</p>
</div><p>Get <strong>IDEXX Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>IDEXX Laboratories</strong> 警报：</p>
</div><ul>
<li>Bullish or Bearish? Vetting Animal Health Care Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>看涨还是看跌？评估动物医疗股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Red Spruce Capital LLC boosted its holdings in shares of IDEXX Laboratories by 1.1% in the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company's stock valued at $912,000 after buying an additional 19 shares during the period. Rise Advisors LLC raised its position in IDEXX Laboratories by 3.9% in the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company's stock valued at $301,000 after buying an additional 21 shares during the last quarter. Sage Mountain Advisors LLC raised its position in IDEXX Laboratories by 3.8% in the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock valued at $267,000 after buying an additional 23 shares during the last quarter. Great Lakes Advisors LLC raised its position in IDEXX Laboratories by 0.9% in the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company's stock valued at $1,078,000 after buying an additional 23 shares during the last quarter. Finally, PDS Planning Inc raised its position in IDEXX Laboratories by 3.9% in the 1st quarter. PDS Planning Inc now owns 641 shares of the company's stock valued at $269,000 after buying an additional 24 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对该股票的持仓进行了调整。Red Spruce Capital LLC 在第二季度将其在 IDEXX Laboratories 的持股增加了 1.1%。Red Spruce Capital LLC 现在拥有 1,701 股公司股票，价值 912,000 美元，在此期间又购买了 19 股。Rise Advisors LLC 在第二季度将其在 IDEXX Laboratories 的持仓提高了 3.9%。Rise Advisors LLC 现在拥有 562 股公司股票，价值 301,000 美元，在上个季度又购买了 21 股。Sage Mountain Advisors LLC 在第一季度将其在 IDEXX Laboratories 的持仓提高了 3.8%。Sage Mountain Advisors LLC 现在拥有 635 股公司股票，价值 267,000 美元，在上个季度又购买了 23 股。Great Lakes Advisors LLC 在第一季度将其在 IDEXX Laboratories 的持仓提高了 0.9%。Great Lakes Advisors LLC 现在拥有 2,567 股公司股票，价值 1,078,000 美元，在上个季度又购买了 23 股。最后，PDS Planning Inc 在第一季度将其在 IDEXX Laboratories 的持仓提高了 3.9%。PDS Planning Inc 现在拥有 641 股公司股票，价值 269,000 美元，在上个季度又购买了 24 股。机构投资者和对冲基金持有公司 87.84% 的股票。</p>
</div><h2>IDEXX Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 股票表现</h2>
</div><p>NASDAQ IDXX opened at $631.19 on Friday. The firm has a 50-day moving average of $634.52 and a 200-day moving average of $535.57. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The stock has a market cap of $50.50 billion, a PE ratio of 52.56, a P/E/G ratio of 4.09 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12.</p>
<div class="lb-trans"><p>NASDAQ IDXX 周五开盘价为 631.19 美元。该公司的 50 日移动平均线为 634.52 美元，200 日移动平均线为 535.57 美元。公司的债务与股本比率为 0.31，速动比率为 0.79，流动比率为 1.11。该股票的市值为 505 亿美元，市盈率为 52.56，市盈增长比率为 4.09，贝塔值为 1.58。IDEXX Laboratories, Inc. 的 52 周低点为 356.14 美元，52 周高点为 688.12 美元。</p>
</div><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period last year, the firm earned $2.44 earnings per share. IDEXX Laboratories's revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.</p>
<div class="lb-trans"><p>IDEXX Laboratories (NASDAQ:IDXX - 获取免费报告) 最近于 8 月 4 日星期一发布了季度财报。该公司报告季度每股收益为 3.63 美元，超出分析师一致预期的 3.28 美元，超出幅度为 0.35 美元。IDEXX Laboratories 的净利润率为 24.41%，股本回报率为 64.42%。该季度的营业收入为 11.1 亿美元，而分析师预期为 10.6 亿美元。去年同期，该公司每股收益为 2.44 美元。与去年同期相比，IDEXX Laboratories 本季度的收入增长了 10.6%。IDEXX Laboratories 已设定 2025 财年的每股收益指导为 12.400-12.760 美元。平均而言，卖方分析师预计 IDEXX Laboratories, Inc. 本年度将发布 11.93 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at IDEXX Laboratories</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 的内部买卖</h2>
</div><p>In related news, EVP Nimrata Hunt sold 7,143 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the transaction, the executive vice president directly owned 18,007 shares of the company's stock, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares in the company, valued at approximately $52,650,885.78. This represents a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 in the last quarter. Company insiders own 0.98% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Nimrata Hunt 于 8 月 6 日星期三出售了 7,143 股公司的股票。股票以 630.43 美元的平均价格出售，总交易额为 4,503,161.49 美元。交易后，该执行副总裁直接持有 18,007 股公司股票，价值约为 11,352,153.01 美元。这笔交易代表其持股减少了 28.40%。该交易已在向证券交易委员会的法律备案中披露，相关信息可通过 SEC 网站获取。此外，首席执行官 Jonathan Jay Mazelsky 于 8 月 6 日星期三出售了 29,260 股公司的股票。股票以 631.98 美元的平均价格出售，总交易额为 18,491,734.80 美元。交易后，首席执行官直接持有 83,311 股公司股票，价值约为 52,650,885.78 美元。这代表其持股减少了 25.99%。该销售的披露信息可以在这里找到。内部人士在上个季度出售了 54,057 股公司股票，价值 34,293,468 美元。公司内部人士持有公司 0.98% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>Several brokerages recently commented on IDXX. Wall Street Zen cut shares of IDEXX Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Sunday, September 28th. BTIG Research increased their target price on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, August 5th. Weiss Ratings restated a &#34;buy (b-)&#34; rating on shares of IDEXX Laboratories in a report on Saturday, September 27th. JPMorgan Chase &amp; Co. increased their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an &#34;overweight&#34; rating in a report on Monday, August 4th. Finally, Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a &#34;buy&#34; rating and a $625.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $656.50.</p>
<div class="lb-trans"><p>几家券商最近对 IDXX 发表了评论。华尔街禅在 9 月 28 日星期日的报告中将 IDEXX Laboratories 的股票评级从 “强力买入” 下调至 “买入”。BTIG Research 在 8 月 5 日星期二的报告中将 IDEXX Laboratories 的目标价格从 545.00 美元上调至 785.00 美元，并给予该股票 “买入” 评级。Weiss Ratings 在 9 月 27 日星期六的报告中重申了对 IDEXX Laboratories 的 “买入（b-）” 评级。摩根大通在 8 月 4 日星期一的报告中将 IDEXX Laboratories 的目标价格从 550.00 美元上调至 675.00 美元，并给予该股票 “增持” 评级。最后，Jefferies Financial Group 在 7 月 1 日星期二开始覆盖 IDEXX Laboratories 的股票。他们设定了 “买入” 评级和 625.00 美元的目标价格。一位研究分析师对该股票给予了强力买入评级，七位给予了买入评级，四位对该公司给予了持有评级。根据 MarketBeat.com，该公司目前的共识评级为 “适度买入”，共识目标价格为 656.50 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on IDXX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 IDXX 股票分析</strong></p>
</div><h2>IDEXX Laboratories Profile</h2>
<div class="lb-trans"><h2>IDEXX Laboratories 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.</p>
<div class="lb-trans"><p>IDEXX Laboratories, Inc. 主要开发、制造和分销产品，服务于非洲、亚太地区、加拿大、欧洲、拉丁美洲及国际市场的伴侣动物兽医、牲畜和家禽、乳制品及水质检测市场。该公司通过三个部门运营：伴侣动物组；水质产品；以及牲畜、家禽和乳制品。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than IDEXX Laboratories</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Why the Precious Metal Nobody Talks About Could Be Your Best Bet</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 IDEXX 实验室</li>
<li>比较和交易高市盈率股票</li>
<li>为什么没人谈论的贵金属可能是你最好的投资选择</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>便宜的 Chipotle？为什么 CMG 股票可能准备反弹</li>
<li>在 52 周高点盈利交易股票</li>
<li>3 只工业股票准备从美联储降息和支出中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding IDXX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 IDXX 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取 IDEXX 实验室公司（NASDAQ:IDXX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IDXX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 IDEXX 实验室吗？</h2>
</div><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 IDEXX 实验室之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而 IDEXX 实验室并不在名单上。</p>
</div><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 IDEXX 实验室目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Three Bridge Wealth Advisors LLC 建立了在 IDEXX 实验室公司的持仓 $IDXX